These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23777014)

  • 21. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L; Garvey M; Mesaros N; Glupczynski Y; Mingeot-Leclercq MP; Piddock LJ; Tulkens PM; Vanhoof R; Van Bambeke F
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
    Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
    J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of quinolone-resistant strains in Streptococcus pneumoniae isolated from paediatric patients since the approval of oral fluoroquinolones in Japan.
    Takeuchi N; Ohkusu M; Hoshino T; Naito S; Takaya A; Yamamoto T; Ishiwada N
    J Infect Chemother; 2017 Apr; 23(4):218-223. PubMed ID: 28159338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression analysis in the potent bactericidal activity of sitafloxacin against Streptococcus pneumoniae.
    Kobayashi I; Kanesaka I; Kanayama Katsuse A; Takahashi H; Okumura R; Nakanishi Y; Kaneko A
    J Infect Chemother; 2019 Apr; 25(4):322-324. PubMed ID: 30366862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
    Balsalobre L; de la Campa AG
    Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae.
    Manzor O; Pawlak J; Saravolatz L
    J Antimicrob Chemother; 1999 Jan; 43(1):31-6. PubMed ID: 10381098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Susceptibility of clinically-isolated bacteria strains to respiratory quinolones and evaluation of antimicrobial agent efficacy by Monte Carlo simulation].
    Kosaka T; Yamada Y; Kimura T; Kodama M; Fujitomo Y; Masaki N; Toshiaki K; Keisuke S; Fujita N
    Jpn J Antibiot; 2016 Feb; 69(1):27-40. PubMed ID: 27290828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of macrolide resistance in Streptococcus pneumoniae.
    Kimura T; Horii T; Morita M; Muramatsu H; Kanno T; Maekawa M
    Chemotherapy; 2003 May; 49(1-2):56-61. PubMed ID: 12714812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.
    Yamaguchi T; Hashikita G; Takahashi S; Itabashi A; Yamazaki T; Maesaki S
    J Infect Chemother; 2005 Oct; 11(5):262-4. PubMed ID: 16258826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antimicrobial and rapid bactericidal activities of sitafloxacin and other agents against Streptococcus pyogenes].
    Namba E; Okumura R; Chiba M; Hoshino K; Tateda K
    Jpn J Antibiot; 2013 Oct; 66(5):293-304. PubMed ID: 24527519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of sitafloxacin against atypical bacteria (2009-2014) and comparison between susceptibility of clinical isolates in 2009 and 2012.
    Amano A; Kishi N; Koyama H; Matsuzaki K; Matsumoto S; Uchino K; Yamaguchi H; Yokomizo A; Mizuno M
    Jpn J Antibiot; 2016 Sep; 69(3):131-142. PubMed ID: 30226949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.
    Chang WL; Kao CY; Wu CT; Huang AH; Wu JJ; Yang HB; Cheng HC; Sheu BS
    Helicobacter; 2012 Jun; 17(3):210-5. PubMed ID: 22515359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
    Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
    Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
    Fujita J; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Tanigawara Y; Cash HL; Kohno S
    J Infect Chemother; 2013 Jun; 19(3):472-9. PubMed ID: 23179958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.